Study #2018-0596
A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Study Status
Open
Treatment Agent
AMG427
Principal Investigator
Farhad Ravandi-Kashani
Description
The goal of this clinical research study is to find the highest tolerable dose of AMG 427 that can be given to patients with acute myeloid leukemia (AML) that is relapsed (has come back) or refractory (has not responded to treatment). The safety and effects of this drug will also be studied. This is the first study using AMG 427 in humans.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: AMG427
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Amgen, Inc.
Study Status
IRB Review and Approval Date: 11/30/2018
Recruitment Status: Open
Projected Accrual: 70
Resources and Links
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase I
Physician name:
Farhad Ravandi-Kashani
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789